Cramer: Valeant fuss a ‘travesty’
The situation surrounding Valeant Pharmaceuticals has transformed the company into a “great mystery,” CNBC’s Jim Cramer said Monday. “The numbers are all over the map. No one knows what the cash flow is; no one knows what the company is
